Biomarkers are essential for performing early diagnosis, monitoring neurodegenerative
disease progression, gauging responses to therapies, and stratifying neurodegenerative …

Modern multianalyte “omics” technologies allow for the identification of molecular signatures
that confer significantly more information than measurement of a single parameter as …

Background The molecular profile of circulating blood can reflect physiological and
pathological events occurring in other tissues and organs of the body and delivers a …

Identification of biomarkers that assess posttransplant risk is needed to improve long-term
outcomes following heart transplantation. The Clinical Trials in Organ Transplantation …

BACKGROUND Identification of heart transplant (HTx) rejection currently relies on
immunohistology and immunohistochemistry. We aimed to identify specific sets of …

There have been major advances in our knowledge of the contribution of DNA sequence
variations to cardiovascular disease and stroke. However, the inner workings of the body …

Cardiac allograft rejection following heart transplantation is challenging to diagnose. Tissue
biopsies are the gold standard in monitoring the different types of rejection. The last decade …

Background Nine mRNA transcripts associated with acute cellular rejection (ACR) in
previous microarray studies were ported to the clinically amenable NanoString nCounter …

Background The purpose of the study is to investigate the relationship between blood and
tissue-derived rejection-related transcripts from blood gene expression profiling (GEP) and …

Background. Given the central role of sarcomeric dysfunction in cardiomyocyte biology and
sarcomere alterations described in endomyocardial biopsies of transplant patients with …